Browse studies, page 1087
Page 1087 of 1,203, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- Comparison of inflammatory markers in type 2 diabetic patients treated with empagliflozin, metformin, and sulfonylurea Journal of Shahrekord University of Medical Sciences, 2023
- Glycemic control and body weight effects of SGLT2 inhibitors (empagliflozin 25 MG, empagliflozin 12.5 MG and dapagliflozin 10 MG) in the treatment of type 2 diabetes mellitus Journal of the ASEAN Federation of Endocrine Societies, 2024
- Effects of empagliflozin alone and in combination with exercise on the soleus muscle in obese type 2 diabetic rats Journal of Physiological Sciences, 2026
- 26-PUB: Real-World Preference for Triple Fixed-Dose Combination of Empagliflozin, Sitagliptin, and Metformin by Various Health Care Specialist in India: Real Impossible Trio Diabetes, 2026
- Comparison of Metformin combined with Empagliflozin or Sitagliptin on Glycemic Status, Renal Function, and Albumiuria in Patients with Type 2 Diabetes Mettitus The Medical Journal of Tikrit University, 2026
- Comparison of mean post-treatment HBA1C levels among patients using sitagliptin plus metformin versus empagliflozin plus metformin for treatment of Type II diabetes mellitus The Professional Medical Journal, 2026
- Self-Reported Symptoms of Empagliflozin Discontinuation – An Online Survey Journal of Diabesity, 2025
- Empagliflozin Perception Mapping Survey Cureus, 2025
- Predictors of asymptomatic ketonemia in outpatients with diabetic kidney disease receiving SGLT-2 inhibitors: a cross-sectional study Diabetology & Metabolic Syndrome, 2026
- Investigation of the effect of SGLT-2 inhibitors on the triglyceride/glucose index in diabetic patients: a cross-sectional study The European Research Journal, 2025
- Evaluation of oxidative stress and inflammatory biomarkers in diabetic patients treated with metformin and empagliflozin: a cross-sectional study Journal of Population Therapeutics and Clinical Pharmacology, 2025
- A comparison of sodium-glucose co-transporter 2 inhibitor kidney outcome trial participants with a real-world chronic kidney disease primary care population Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2024
- Urinary tract infections, risk factors and antimicrobial resistance patterns in heart failure patients on sodium-glucose transporter 2 inhibitors: Evidence from Jakaya Kikwete Cardiac Institute in Tanzania PloS one, 2026
- Association of SGLT2 Inhibitor Use with Glycosuria, Pyuria, Urinary Symptoms, and Significant Urine Culture Positivity in Adults with Type 2 Diabetes: A Prospective Cross-Sectional Study Medicina (Kaunas, Lithuania), 2026
- Association between SGLT-2 inhibitor use and retinal microvascular parameters in patients with Type 2 diabetes mellitus: A cross-sectional study Journal of diabetes and its complications, 2026
- How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area Journal of diabetes research, 2019
- Comparative analysis of serious adverse effects of antidiabetic drugs and complications associated with type II diabetes mellitus BMC pharmacology & toxicology, 2026
- A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2 inhibitor empagliflozin Annals of Saudi medicine, 2018
- Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice Advances in therapy, 2019
- Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes Pharmacogenetics and genomics, 2017
- Finerenone Prescriptions in the United States (2021-2024) by Physician Specialty: Analysis of Use and Potential in the Cardiovascular-Kidney-Metabolic Space Journal of the American Heart Association, 2026
- Electronic Cigarette Use and Cigarette-Smoking Cessation Attempts Among Stroke Survivors in the US. JAMA neurology, 2021
- Early potential safety signals for gliptins and gliflozins using real-world pharmacy data compared to spontaneous reporting PloS one, 2026
- Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study BMJ open diabetes research & care, 2019
- Prescribing patterns and factors associated with sodium-glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease CMAJ open, 2023
- National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020 Journal of the American Heart Association, 2022
- Use of Antihyperglycemic Medications in U.S. Adults: An Analysis of the National Health and Nutrition Examination Survey Diabetes care, 2020
- The beneficial effects of empagliflozin-metformin combination on cardiovascular risk factors in type 2 diabetes mellitus patients Naunyn-Schmiedeberg's archives of pharmacology, 2026
- Efficacy and safety of empagliflozin in the treatment of glycogen storage disease-associated inflammatory bowel disease Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2025
- Methodology of clinical trials on sodium-glucose cotransporter 2 inhibitors registered on ClinicalTrials.gov: a cross-sectional study BMC medical research methodology, 2024
- Investigation on the treatment of empagliflozin in glycogen storage disease type Ⅰb Zhonghua er ke za zhi = Chinese journal of pediatrics, 2024
- Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY® study Cardiovascular diabetology, 2022
- Characteristics, interventions and outcomes of patients with valvular heart disease hospitalised in China: a cross-sectional study BMJ open, 2021
- Coverage, Formulary Restrictions, and Affordability of Sodium-Glucose Cotransporter 2 Inhibitors by US Insurance Plan Types JAMA health forum, 2021
- Type 2 diabetes patients requiring empagliflozin in Southeast of Iran: Frequency and guideline adherence (2022-2023) Hipertension y riesgo vascular, 2024
- Empagliflozin Use among Patients with Heart Failure in the Outpatient Department of Medicine in a Tertiary Care Centre JNMA; journal of the Nepal Medical Association, 2023
- Assessment of Prevalence, Awareness, and Characteristics of Isolated Systolic Hypertension Among Younger and Middle-Aged Adults in China JAMA network open, 2020
- Symptoms of depression and active smoking among survivors of stroke and myocardial infarction: An NHANES analysis Preventive medicine, 2020
- Association of long-term exposure to PM2.5 with hypertension prevalence and blood pressure in China: a cross-sectional study BMJ open, 2021
- The effect of Empagliflozin on alleviating C4d over-activation in Diabetic kidney disease The American journal of the medical sciences, 2025
- Adherence to Guideline-Recommended Cancer Screening in Stroke Survivors: A Nationwide Analysis Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2022
- Severe hypertension in China: results from the China PEACE million persons project Journal of hypertension, 2021
- Impact of Cigarette Smoking and Its Interaction with Hypertension and Diabetes on Cognitive Function in Older Americans Journal of Alzheimer's disease : JAD, 2022
- Comparative assessment of treatment outcomes of empagliflozin add-on metformin and sitagliptin add-on metformin therapies in uncontrolled type 2 diabetes mellitus: findings from an observational study in Pakistan Journal of health, population, and nutrition, 2025
- SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO/ROS imbalance Cardiovascular research, 2025
- Fournier’s Gangrene in a Patient with Type 2 Diabetes Mellitus Treated with Empagliflozin: A Case Report Drug Safety - Case Reports, 2019
- Efficacy and safety of empagliflozin (SGLT2 inhibitor) in Bangladeshi patients with type 2 diabetes mellitus International Journal of Research in Medical Sciences, 2025
- 1491-P: Insights from 1,062 Clinicians—Evaluating the Efficacy and Clinical Utility of Empagliflozin-Linagliptin Combination Therapy in T2DM Management Diabetes, 2025
- Non-carbohydrate anaplerotic therapy counters empagliflozin-induced diabetic ketosis Nutrition & Diabetes, 2025
- Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury Cardiovascular Diabetology, 2018
- Empagliflozin-Mediated Lithium Excretion: A Case Study and Clinical Applications The American journal of case reports, 2020
- A case of ureteral fungal mass removal in a patient taking empagliflozin CEN Case Reports, 2021
- Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report Italian Journal of Pediatrics, 2021
- Long-term efficacy of empagliflozin as an add-on treatment for chronic SIAD: a case report and literature review HORMONES, 2023
- Empagliflozin combined with bortezomib in the treatment of heavy and light chain amyloidosis with secondary diabetes: A case report Medicine, 2025
- Euglycemic diabetic ketoacidosis in a neurosurgical patient on empagliflozin: a case report Journal of Neurocritical Care, 2025
- Increase in glycated haemoglobin concentrations after unwarranted prescription changes Diabetes, obesity and metabolism, 2018
- Dapagliflozin-Associated Diabetic Ketoacidosis American Journal of Therapeutics, 2018
- Rapid-onset clozapine-induced hyperglycaemia: pathways of glycaemic dysregulation BMJ Case Reports, 2021
- Use of Sodium-Glucose Cotransporter-2 Inhibitor for Diabetes Management in Patients Following Kidney Transplantation Journal of Pharmacy Technology, 2023
- Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy Acta Diabetologica, 2021
- P-31 GLP1 receptor agonist in end-stage kidney disease: Are they safe and effective? JCEM Case Reports, 2024
- Judicious use of modern technology with antihyperglycemic agents: The changing landscape of type 2 diabetes management Journal of Diabetology, 2024
- Intraoperative Diagnosis of Sodium-Glucose Transporter-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis Cureus, 2024
- Creatine Phosphokinase Level Accompanied with Macro-Creatine Phosphokinase Type 1 Negatively Correlates with Plasma Glucose Control in a Patient with Type 2 Diabetes Mellitus Dubai Diabetes and Endocrinology Journal, 2022
- Differing effects of Nefecon and Sparsentan in a patient with recurrent IgA nephropathy post-kidney transplantation Clinical Kidney Journal, 2026
- Impact of Sodium-glucose Co-transporter 2 Inhibitors on Bone Mineral Biomarkers and Renal Progression in Diabetic Kidney Disease: A Prospective Observational Study Indian Journal of Kidney Diseases, 2026
- Evaluation and efficacy of SGLT2 inhibitors in diabetes mellitus and heart failure patients in telangana Indian Journal of Health Care Medical & Pharmacy Practice, 2025
- Use of emgliflozin in the prevention of cardotoxicity.The EMPACARD - PILOT TRIAL. 12 - months Follow -up European Heart Journal, Supplement, 2025
- Bridging Cardiorenal and Hepatic Disease: The Emerging Role of SGLT2 Inhibitors in Cirrhosis Cardiology in Review, 2025
- Risk of depression and dementia among individuals treated with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists Current Opinion in Psychiatry, 2025
- SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation Cell Metabolism, 2024
- Triple Therapy with Empagliflozin, Linagliptin and Gliclazide in a Patient who Refuses Insulin: New Solutions to an Old Problem 2016
- Sodium-glucose cotransporter 2 inhibitor-induced euglycemic diabetic ketoacidosis in a patient with coronavirus disease 2019: a case report Journal of Medical Case Reports, 2022
- Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature AACE Clinical Case Reports, 2020
- 575: emphysematous kidney and pyelonephritis in a diabetic woman managed with empagliflozin 2020
- Severe Hypernatraemic Dehydration and Unconsciousness in a Care-Dependent Inpatient Treated with Empagliflozin Drug Safety - Case Reports, 2017
- Euglycemic diabetic ketoacidosis following sleeve gastrectomy in a patient with type 2 diabetes on a sodium-glucose co-transporter 2 inhibitor: a case report and call for practice guidelines AME Case Reports, 2023
- THU359 A Classical Case Of SGLT-2 Inhibitor Euglycemic Ketoacidosis In A Patient With Glucotoxicity Journal of the Endocrine Society, 2023
- THU380 A Case Of Alpelisib Induced Diabetic Ketoacidosis (Dka) In A Patient With Type 2 Diabetes Mellitus And Rechallenge With SGLT2 Inhibitor Journal of the Endocrine Society, 2023
- Evaluation of the Effect of Empagliflozin Therapy on T Helper 22 Cell-Related Factors in Patients with Type 2 Diabetes Mellitus Avicenna Journal of Clinical Medicine, 2021
- An interesting experience with empagliflozin: unidentified body odor. Acta Endocrinologica, 2021
- Empagliflozin in paroxysmal or persistent atrial fibrillation: a possible antiarrhythmic effect Diabetes Updates, 2021
- Correction of Over-Dosed Insulin in a Type-2-Diabetic Associates With a Better Control of Glycemia and Arterial Hypertension: A Case Report 2020
- Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea Endocrinology and Metabolism, 2020
- Use of a Sodium-Glucose Cotransporter 2 Inhibitor, Empagliflozin, in a Patient with Rabson-Mendenhall Syndrome Hormone Research in Paediatrics, 2021
- Correction of over-dosed insulin in a type-2- diabetic led to a better control of glycemia and arterial hypertension: a case report Journal of Pharmacy and Pharmacology Research, 2021
- Euglycemic Ketoacidosis Induced by SGLT2 Inhibitor in Latent Autoimmune Diabetes in Adults: A Case Report International Journal of Medical and Biomedical Studies, 2024
- 8088 Connecting the Dots: Semaglutide, Constipation, and Diverticulitis - A case report Journal of the Endocrine Society, 2024
- Efficacy of sodium-glucose cotransporter 2 inhibitor with glucagon-like peptide-1 receptor agonist for the glycemic control of a patient with Prader-Willi syndrome: a case report Clinical Pediatric Endocrinology, 2020
- Cardiovascular and Renal Benefits of Sglt2 Inhibitors in Chronic Hemodialysis: A Case Report BULLETIN OF THE TRANSILVANIA UNIVERSITY OF BRASOV SERIES VI - MEDICAL SCIENCES, 2026
- Pharmacometrics-Enhanced Bayesian Borrowing for Pediatric Extrapolation – A Case Study of the DINAMO Trial Therapeutic Innovation and Regulatory Science, 2024
- SAT-520 Tirzepatide-associated Interstitial Kidney Injury: A Case Report Journal of the Endocrine Society, 2025
- Empagliflozin and intermittent fasting as a strategy to mitigate anthracycline-induced cardiotoxicity Scientific Reports, 2026
- The impact of empagliflozin and metformin on cardiac parameters in patients with mid-range ejection fraction heart failure without diabetes Journal of Medicine and Life, 2024
- MON-648 A Deadly Duo: Rapid-Onset Lactic Acidosis and Euglycemic DKA in a Young Male with Normal Renal Function on Metformin and Empagliflozin Resumption Journal of the Endocrine Society, 2025
- A prospective observational case-controlled pilot study protocol on natural killer cell activity in patients with type 2 diabetes mellitus taking empagliflozin 2020
- Impact of early administration of empagliflozin in patients with acute decompensated heart failure on medium-term prognosis (3 and 6 months) Rational Pharmacotherapy in Cardiology, 2025
- Effectiveness of Empagliflozin-Linagliptin Fixed-Dose Combination on Chronic Kidney Disease Outcomes in Patients With Type 2 Diabetes in a Real-World Setting Cureus, 2025
- Characteristic dysbiosis in patients with type 2 diabetes and hyperuricemia, and the effect of empagliflozin on gut microbiota World Journal of Diabetes, 2025
